Replies to post #224313 on Biotech Values

[Bickema]

Biotech Has Gotten Crowded, but There’s Plenty of Room for Genfit, Exec Says
https://www.barrons.com/articles/corn-prices-likely-to-rise-as-floods-cut-output-and-new-ethanol-guidelines-lift-demand-51553772601

[DewDiligence]

GNFT inks Elafibranor-commercialization deal for Greater China*:

https://www.globenewswire.com/news-release/2019/06/24/1873306/0/en/GENFIT-GENFIT-and-Terns-Pharmaceuticals-Announce-228MM-Strategic-Partnership-to-Develop-and-Commercialize-Elafibranor-in-Greater-China.html

Genfit today announced the signing of a licensing and collaboration agreement with Terns Pharmaceuticals, a global biopharmaceutical company based in the U.S. and China with a focus on developing novel and combination therapies to treat liver disease. Under the agreement, Terns will have the rights to develop and commercialize elafibranor, GENFIT’s proprietary compound, in Greater China, for the treatment of non-alcoholic steatohepatitis (NASH) and primary biliary cholangitis (PBC).

Under the terms of the licensing agreement, GENFIT will receive an upfront payment from Terns of $35 million and will be eligible to receive up to $193 million in potential clinical, regulatory and commercial milestone payments. …GENFIT will be entitled to receive mid-teen percentage royalties from Terns based on sales in the territory.

As part of the deal, GENFIT and Terns will also undertake joint R&D projects in liver disease, including the development of elafibranor in combination with Terns’ proprietary compounds.

*Includes mainland China, Hong Kong, Macau, and Taiwan.